Serious liver injury being observed in patients without cirrhosis taking Ocaliva (obeticholic acid) to treat primary biliary cholangitis
Similar Posts
MHRA seeks input on AI regulation at ‘pivotal moment’ for healthcare
National Commission is seeking evidence to shape regulation of AI in healthcare and support the UK’s ambition for a world-leading, AI-enabled NHS
Sarfez Pharmaceuticals, Inc. – 708901 – 04/25/2025
False & Misleading Claims/MisbrandedCDER SBIA Chronicles
FDA/CDER SBIA Chronicles, the bi-monthly newsletter of the CDER Small Business and Industry Assistance team, provides industry with useful information to assist in all aspects of drug marketing and regulationWhat You Should Know about Eye Drops
Ophthalmic drug products, such as eye drops, pose a heightened risk of harm to users because drugs applied to the eyes bypass some of the body’s natural defenses. Any drug used in the eyes must be sterile to reduce the risk of infection. Eye drops are available by prescription or sold as OTCs.Dr Alison Cave: Pharmacists are on the frontline of medicines safety – and your reports make all the difference
As part of #MedSafetyWeek, the MHRA’s Chief Safety Officer reflects in The Pharmacist on the vital role pharmacists play in keeping medicines and medical devices safe.
Field Safety Notices: 11 to 15 August 2025
List of Field Safety Notices from 11 to 15 August 2025.